Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

INTRODUCTION: Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Y K Onno, Bruce, Ian N, Diamond, Betty, Furie, Richard A, van Vollenhoven, Ronald F, Gordon, David, Groark, James, Henderson, Robert B, Oldham, Mary, Tak, Paul P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475247/
https://www.ncbi.nlm.nih.gov/pubmed/30898822
http://dx.doi.org/10.1136/bmjopen-2018-025687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475247/
https://www.ncbi.nlm.nih.gov/pubmed/30898822
http://dx.doi.org/10.1136/bmjopen-2018-025687

Ejemplares similares